Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia (GEMS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia. The patients suffering from that condition frequently wake up during the night, their sleep is nonrestorative and they suffer from a significant distress or impairment in their daily activities consecutive to insomnia.
| Condition | Intervention | Phase |
|---|---|---|
|
Sleep Initiation and Maintenance Disorders Insomnia |
Drug: eplivanserin (SR46349) Drug: placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study |
- Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire) [ Time Frame: at week 12 ] [ Designated as safety issue: No ]
- Change from baseline of the mean of the FOSQ items 1 and 2 (concentration/memory) [ Time Frame: at week 12 ] [ Designated as safety issue: No ]
- Change from baseline of the mean of the FOSQ items 4 and 10 (hobby/work) [ Time Frame: at week 12 ] [ Designated as safety issue: No ]
| Enrollment: | 967 |
| Study Start Date: | November 2005 |
| Study Completion Date: | January 2008 |
| Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
5 mg/day
|
Drug: eplivanserin (SR46349)
oral administration
|
| Placebo Comparator: 2 |
Drug: placebo
oral administration
|
Detailed Description:
The study is being conducted world-wide. It consists of 3 segments:
- Segment A: 7-day run-in (screening).
- Segment B: 12-week double blind treatment.
- Segment C: 2-week Run-out period
An IVR system will be used to register patients, report completion of certain phases of the trial, and to discontinue patients. In addition, a daily patient diary will be completed via the IVRS. A central laboratory for processing blood specimens will be used. Patients will be requested to complete questionnaires at each visit, including completion of the FOSQ (Functional Outcome of Sleep Questionnaire) the evening prior to each visit.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Out patients
- Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I criteria
- Based on patient's information, the patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month
- Patient must report impact daytime functioning associated with sleep maintenance insomnia as measured by question 3 of Insomnia Severity Index at screening visit and randomization visit.
Exclusion Criteria:
- Females who are lactating or pregnant
- Woman of childbearing potential with a positive serum beta human chorionic gonadotropin pregnancy test at screening and not using an acceptable form of contraception
- Patients presenting with acute or chronic pain resulting in insomnia
- Patients with history of epilepsy or seizures
- Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising more than 5 glasses/day
- Evidence of any clinically significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety
- BMI >32
- Acute or chronic pain resulting in insomnia
- Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental retardation, or dementia
- Clinically significant and abnormal EKG (QTc interval >=500 msec)
- Positive for hepatitis B or C
- Serious head injury or stroke within 1 year
- Use of OTC medications such as valerian root, kava, melatonin, St. John's Wort, or alluna; prescription sleep medications or anxiolytics within 1 week or 5 half-lives
- Participation in another trial within two month before the screening visit
- Use of any substance with psychotropic effects or properties known to affect sleep/wake
- Unable to complete the study questionnaires
- Night shift workers, and individuals who nap 3 or more times per week over the preceding month
History of:
- Primary hypersomnia
- Narcolepsy
- Breathing-related sleep disorder (such as sleep apnea)
- Circadian rhythm sleep disorder
- Parasomnia (somnambulism)
- Dyssomnia (such as periodic leg movements)
Contacts and Locations| United States, New Jersey | |
| Sanofi-Aventis Administrative Office | |
| Bridgewater, New Jersey, United States, 08807 | |
| Argentina | |
| Sanofi-Aventis Administrative Office | |
| Buenos Aires, Argentina | |
| Australia | |
| Sanofi-Aventis Administrative Office | |
| Macquarie Park, Australia | |
| Canada | |
| Sanofi-Aventis Administrative Office | |
| Laval, Canada | |
| Chile | |
| Sanofi-Aventis Administrative Office | |
| Santiago, Chile | |
| Czech Republic | |
| Sanofi-Aventis Administrative Office | |
| Praha, Czech Republic | |
| France | |
| Sanofi-Aventis Administrative Office | |
| Paris, France | |
| Germany | |
| Sanofi-Aventis Administrative Office | |
| Berlin, Germany | |
| Mexico | |
| Sanofi-Aventis Administrative Office | |
| Mexico, Mexico | |
| Netherlands | |
| Sanofi-Aventis Administrative Office | |
| Gouda, Netherlands | |
| Spain | |
| Sanofi-Aventis Administrative Office | |
| Barcelona, Spain | |
| United Kingdom | |
| Sanofi-Aventis Administrative Office | |
| Guildford, United Kingdom | |
| Study Director: | ICD | Sanofi |
More Information
No publications provided
| Responsible Party: | ICD Study Director, sanofi-aventis |
| ClinicalTrials.gov Identifier: | NCT00253968 History of Changes |
| Other Study ID Numbers: | LTE6217, EudraCT: 2005-003080-23 |
| Study First Received: | November 14, 2005 |
| Last Updated: | November 29, 2010 |
| Health Authority: | United States: Food and Drug Administration France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Sanofi:
|
Primary Insomnia Sleeplessness Early Awakening Chronic Insomnia |
Additional relevant MeSH terms:
|
Sleep Initiation and Maintenance Disorders Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases Mental Disorders SR 46349B Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents Platelet Aggregation Inhibitors Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013